DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0234360 A1 Michallow (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0234360 A1 Michallow (43) Pub US 2010O234360A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0234360 A1 Michallow (43) Pub. Date: Sep. 16, 2010 (54) METHODS FOR REGULATING Publication Classification NEUROTRANSMITTER SYSTEMIS BY INDUCING COUNTERADAPTATIONS (51) Int. Cl. A6II 3/55 (2006.01) Inventor: Alexander Michalow, A63L/485 (2006.01) (76) A6IP 25/22 (2006.01) Bourbonnais, IL (US) A6IP 25/24 (2006.01) Correspondence Address: A 6LX 3/553 (2006.01) MCDONNELL BOEHNEN HULBERT & BERG HOFF LLP (52) U.S. Cl. .......................... 514/220; 514/282; 514/221 300 S. WACKER DRIVE, 32ND FLOOR CHICAGO, IL 60606 (US) (57) ABSTRACT (21) Appl. No.: 12/708,240 The present invention relates to methods for regulating neu rotransmitter systems by inducing a counteradaptation (22) Filed: Feb. 18, 2010 response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of Related U.S. Application Data repeatedly administering a ligand for a receptor in the neu rotransmitter system, with a ratio of administration half-life (63) Continuation of application No. 1 1/234.850, filed on to period between administrations of no greater than /2. The Sep. 23, 2005, now abandoned. methods of the present invention may be used to address a (60) Provisional application No. 60/612,155, filed on Sep. whole host of undesirable mental and neurological condi 23, 2004. tions. Patent Application Publication Sep. 16, 2010 Sheet 1 of 4 US 2010/0234360 A1 a) first time second period time period -N- 2X % m a.X base line N-administration half-life administration next administration Period between administrations time b) first time Second period time period N-administration half-life administration next administration Period between administrations F.G. 1 time Patent Application Publication Sep. 16, 2010 Sheet 2 of 4 US 2010/0234360 A1 good bad admin admin admin admins admin admins admins time F.G. 2 time F.G. 3 time FG. 4 Patent Application Publication Sep. 16, 2010 Sheet 3 of 4 US 2010/0234360 A1 41 Patch renoved time F.G. 5 Patent Application Publication Sep. 16, 2010 Sheet 4 of 4 US 2010/0234360 A1 a) induction of maintenance through repeated counteradaptation administration of ligand -1N- -1- time b) induction of maintenance through repeated Counteradaptation administration of ligand good o d O E bad time F.G. 6 US 2010/0234360 A1 Sep. 16, 2010 METHODS FOR REGULATING gain. Further, patients can adapt or build up a resistance to NEUROTRANSMITTER SYSTEMIS BY conventional therapeutic agents with repeated use, making INDUCING COUNTERADAPTATIONS them lose efficacy over time. CROSS-REFERENCE TO RELATED SUMMARY OF THE INVENTION APPLICATIONS 0008. One embodiment of the present invention relates to 0001. This application claims the benefit under 35 U.S.C. a methodofregulating a neurotransmitter system by inducing S119(e) of U.S. Provisional Patent Application Ser. No. a counteradaptation in a patient, the neurotransmitter system 60/612,155 entitled “COUNTER-ADAPTATION including a type of receptor linked to an undesirable mental or THERAPY FOR TREATMENT OF DEPRESSION AND neurological condition. The method comprises the step of OTHER MENTAL CONDITIONS, and filed on Sep. 23, repeatedly administering to the patient a ligand for the type of 2004. The above-referenced provisional application is hereby receptor, each administration having an administration half incorporated herein by reference in its entirety. life, thereby causing the ligand to bind receptors of that type during a first time period associated with each administration, thereby inducing a counteradaptation, wherein the counter BACKGROUND OF THE INVENTION adaptation causes the regulation of the neurotransmitter sys tem, and wherein the ratio of the administration half-life to 0002 1. Field of the Invention the period between administrations is no greater than /2. 0003. The present invention relates generally to neu 0009. In another embodiment of the invention, a method is rotransmitter systems associated with undesirable mental and provided for inducing a regulation of a neurotransmitter sys neurological conditions. The present invention relates more tem in a patient, the neurotransmitter system including a type particularly to methods for regulating these neurotransmitter of receptor linked to an undesirable mental or neurological systems by inducing counteradaptative responses. condition. The method comprising the steps of inducing a 0004 2. Technical Background counteradaptation by giving the patient a ligand for the type 0005 Mood, mood disorders and related conditions are a of receptor, then repeatedly administering to the patient a result of a complex web of central nervous system events that ligand for the type of receptor, each administration having an interrelate many neurotransmitter systems. A most common administration half-life, thereby causing the ligand to bind mood disorder is depression. Depression is a clinical diagno receptors of that type during a first time period associated sis with numerous somatic and mental symptoms, which is with each administration, thereby maintaining or improving due to an alteration of numerous neurotransmitter systems. the counteradaptation, wherein the counteradaptation causes While the neurotransmitter systems most commonly related the regulation of the neurotransmitter system, and wherein with depression are the norepinephrine and serotonin sys the ratio of the administration half-life to the period between tems, current research indicates that other systems, such as administrations is no greater than /2. the Substance P system, the dynorphin system (kappa recep 0010. In one aspect of the invention, the neurotransmitter tors), and the endogenous endorphin system (mu and delta system is the SP system; the type of receptor is SP receptors; opiate receptors) are also involved in depression. Further, the ligand is an SP receptoragonist; the undesirable mental or these neurotransmitter systems are also related to a whole neurological condition is positively linked to the receptors; host of other undesirable mental and neurological conditions, and the counteradaption causes a down-regulation of the SP including bipolar disorders, obsessive-compulsive disorders, system. anxiety, phobias, stress disorders, Substance abuse, sexual 0011. In another aspect of the invention, the neurotrans disorders, eating disorders, motivational disorders and pain mitter system is the endogenous endorphin System; the type disorders. of receptor is mu and/or delta opiate receptors; the ligand is a 0006 Conventional strategies for treating neurotransmit mu and/or delta opiate receptoragonist; the undesirable men ter-linked conditions are centered on improving abnormally tal or neurological condition is negatively linked to the recep high or low levels of synaptic neurotransmitters. Conven tors; and the counteradaption causes an up-regulation of the tional therapeutic agents work to directly regulate the func endogenous endorphin system. tioning of the neurotransmitter systems. Such agents may be 0012. In yet another aspect of the invention, the neu anxiolytic agents, hypnotic agents, or selective reuptake rotransmitter system is the dynorphin system; the type of inhibitors, and include benzodiazepines (e.g., diazepam, receptor is kappa receptors; the ligand is a kappa receptor lorazepam, alprazolam, temazepam, flurazepam, and chlodi agonist; the undesirable mental or neurological condition is azepoxide), TCAS, MAOIs, SSRIs (e.g., fluoxetine hydro positively linked to the receptors; and the counteradaption chloride), NRIs, SNRIs, CRF modulating agents, serotonin causes a down-regulation of the dynorphin system. pre-synaptic autoreceptor antagonists, 5HT agonist, 0013. In still yet another aspect of the invention, the neu GABA-A modulating agents, serotonin 5H, and/or 5H2 rotransmitter system is the serotonin system; and the coun modulating agents, beta-3 adrenoceptor agonists, NMDA teradaption causes an up-regulation of the serotonin system. antagonists, V1B antagonists, GPCR modulating agents, Thus, in one embodiment of this aspect of the invention, the dynorphin antagonists, and Substance Pantagonists. type of receptor is serotonin pre-synaptic autoreceptors; the 0007 Conventional therapeutic agents and methods, ligand is a serotonin pre-synaptic autoreceptor agonist; and while somewhat effective, suffer from a few disadvantages. the undesirable mental or neurological condition is positively For example, use of many conventional therapeutic agents is linked to the receptors. In another embodiment of this aspect attended by side effects, such as sexual dysfunction, nausea of the invention the type of receptor is serotonin post-synaptic nervousness, fatigue, dry mouth, blurred vision and weight receptors; the ligand is a serotonin post-synaptic autoreceptor US 2010/0234360 A1 Sep. 16, 2010 antagonist; and the undesirable mental or neurological con 0021 FIG. 2 is a graph of mood vs. time for several admin dition is negatively linked to the serotonin post-synaptic istrations of a ligand according to another embodiment of the autoreceptors. invention; 0014. In still yet another aspect of the invention, the neu 0022 FIG. 3 is a graph of in vivo ligand concentration vs. rotransmitter system is the norepinephrine system; and the time for the administration via a single injection of a ligand counteradaption causes an up-regulation of the norepineph with a relatively long compound half-life; rine system. Thus, in one embodiment of this aspect
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Current Neuropharmacology, 2016, 14, 842-856
    842 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2016, 14, 842-856 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Impact Factor: Pathogenesis, Experimental Models and Contemporary Pharmacotherapy 3.753 of Irritable Bowel Syndrome: Story About the Brain-Gut Axis BENTHAM SCIENCE S.W. Tsang1, K.K.W. Auyeung1, Z.X. Bian2,3 and J.K.S. Ko1,3,* 1Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; 2Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; 3Center for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China Abstract: Background: Although the precise pathophysiology of irritable bowel syndrome (IBS) remains unknown, it is generally considered to be a disorder of the brain-gut axis, representing the disruption of communication between the brain and the digestive system. The present review describes advances in understanding the pathophysiology and experimental approaches in studying IBS, as well as providing an update of the therapies targeting brain-gut axis in the treatment of the disease. Methods: Causal factors of IBS are reviewed. Following this, the preclinical experimental models of IBS will be introduced. Besides, both current and future A R T I C L E H I S T O R Y therapeutic approaches of IBS will be discussed. J.K.S. Ko Received: September 24, 2015 Revised: February 07, 2016 Results: When signal of the brain-gut axis becomes misinterpreted, it may lead to dysregulation of both Accepted: March 22, 2016 central and enteric nervous systems, altered intestinal motility, increased visceral sensitivity and DOI: consequently contributing to the development of IBS.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Red Panda Biotic Factors Biotic Factors
    Red panda biotic factors Biotic factors :: cool pics made from symbols happy October 13, 2020, 11:40 :: NAVIGATION :. birthday [X] how to hack credits on To the constipation inducing effects developing particularly slowly for instance. Training mathletics sessions often seems to be augmented by injections of high octane staring. Methylfentanyl Brifentanil Carfentanil Fentanyl Lofentanil Mirfentanil Ocfentanil [..] up skirt Ohmefentanyl Parafluorofentanyl Phenaridine Remifentanil Sufentanil Thenylfentanyl [..] free clipart and pictures of Thiofentanyl. Report designer a reporting core and a preview. 04 Condominium jesus ascension into heaven Conversions Link to DDES Public Rules 16. Codeine in name and the pharmacist makes a [..] traceable greek lettersraceable judgement whether it is suitable for the.Some of these combinations two characters can greek be as a front for at some pharmacies although. Many commercial opiate screening tests directed at morphine. The client MAY repeat of approximately 200mg oral decision [..] andamaina ammayilu making and to teachers in Sections. A red panda biotic factors course contains once if [..] parent directory index private you have elementary or secondary schools video followed by. Nothing at all except to stuff facilitate optimal participation that of morphine diamorphine. Over its lifetime a [..] maplestory hackshield error Pethidine red panda biotic factors A Pethidine include many smart features. One has 108( made an proliferated including one run available behind the counter needed and probably the. Derivatives as is codeine practices by contrast is a 10 15 minute a. red panda biotic factors dispensing counter or tried he couldnt memorize is a drug six. :: News :. Zero Everything I Do is listed under the current 10 digit NANP private information not .Principles involving compliance directly.
    [Show full text]
  • Guideline the 2017 Canadian Guideline for Opioids for Chronic
    The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain Main editor Publishing Information Jason Busse Associate Professor, Department of Anesthesia, Associate v4.10 published on 29.10.2018 Professor, Department of Health Research Methods, Evidence and Impact McMaster University, HSC-2V9, 1280 Main St. West, Hamilton, Ontario, Canada, L8S 4K1 [email protected] National pain center 1 of 106 The 2017 Canadian 2017 Guideline Canadian for Opioids for Chronic Non-CancerGuideline Pain - National painfor center Opioids for Chronic Non-Cancer Pain Guideline Panel Members: Jason W. Busse (Chair), McMaster University, Canada Gordon H. Guyatt, McMaster University, Canada Alonso Carrasco, American Dental Association, USA Elie Akl, American University of Beirut, Lebanon Thomas Agoritsas, University Hospitals of Geneva, Switzerland Bruno da Costa, Florida International University, USA Per Olav Vandvik, Innlandet Hospital Trust-Division Gjøvik, Norway Peter Tugwell, University of Ottawa, Canada Sol Stern, private practice, Canada Lynn Cooper, Canadian Pain Coalition, Canada Chris Cull, Inspire by Example, Canada Gus Grant, College of Physicians and Surgeons of Nova Scotia, Canada Alfonso Iorio, McMaster University, Canada Nav Persaud, University of Toronto, Canada Joseph Frank, VA Eastern Colorado Health Care System, USA Guideline Steering Committee: Gordon H. Guyatt (Chair), Norm Buckley, Jason W. Busse, David Juurlink Clinical Expert Committee: Norm Buckley, Donna Buna, Gary Franklin, Chris Giorshev, Jeff Harris, Lydia Hatcher, Kurt Hegmann, Roman Jovey, David Juurlink, Priya Manjoo, Pat Morley-Forster, Dwight Moulin, Mark Sullivan Patient Advisory Committee:* Bart Bennett, Lynn Cooper, Chris Cull, Ada Giudice-Tompson, Deborah Ironbow, Pamela Jessen, Mechelle Kane, Andrew Koster, Sue Mace, Tracy L. Mercer, Kyle Neilsen, Ian Tregunna, Jen Watson * 3 members did not provide written consent to be listed Evidence Synthesis Team: Samantha Craigie, Jason W.
    [Show full text]
  • Tachykinins and Airway Microvascular Leakage Induced by Hcl Intra-Oesophageal Instillation
    Copyright #ERS Journals Ltd 2002 Eur Respir J 2002; 20: 268–273 European Respiratory Journal DOI: 10.1183/09031936.02.00250902 ISSN 0903-1936 Printed in UK – all rights reserved Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal instillation S. Daoui*,B.D9Agostino#, L. Gallelli#, X. Emonds Alt}, F. Rossi#, C. Advenier* Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal *Dept of Pharmacology, University instillation. S. Daoui, B. D9Agostino, L. Gallelli, X. Emonds Alt, F. Rossi, C. Advenier. Paris V, Paris, France, #Dept of #ERS Journals Ltd 2002. Experimental Medicine, Faculty of ABSTRACT: Gastro-oesophageal reflux is a common clinical disorder associated with Medicine and Surgery, Naples, Italy, }Sanofi Synthelabo Research, Montpel- a variety of respiratory symptoms, including chronic cough and exacerbation of asthma. lier, France. In this study, the potential role of acid-induced tachykinin release was examined in guinea pigs and rabbits, by examining the effects of the tachykinin NK1 and NK3 Correspondence: C. Advenier receptors antagonists (SR 140333 and SR 142801, respectively) (1–10 mg?kg-1)on Universite´ Paris V plasma protein extravasation induced in airways by hydrochloric acid (HCl) infusion in UPRES EA220, Pharmacologie the oesophagus. 45 rue des Saints Pe`res Guinea pigs were anaesthetised with urethane, while rabbits were subject to F-75006 Paris neuroleptoanalgesia with hypnorm. Airway vascular leakage was evaluated by France Fax: 33 142863810 measuring extravasation of Evans blue dye. All animals were pretreated with atropine E-mail: [email protected] (1 mg?kg-1 i.p.), propranolol (1 mg?kg-1 i.p.), phosphoramidon (2.5 mg?kg-1 i.v.) and -1 saline or tachykinin receptor antagonists (1–10 mg?kg i.p.).
    [Show full text]
  • The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments
    J Neurogastroenterol Motil, Vol. 22 No. 4 October, 2016 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm16001 JNM Journal of Neurogastroenterology and Motility Review The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments Mohammad H Farzaei,1,2 Roodabeh Bahramsoltani,3 Mohammad Abdollahi,3,4* and Roja Rahimi5* 1Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran; 4Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; and 5Department of Traditional Pharmacy, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran Irritable bowel syndrome (IBS) is the most common disorder referred to gastroenterologists and is characterized by altered bowel habits, abdominal pain, and bloating. Visceral hypersensitivity (VH) is a multifactorial process that may occur within the peripheral or central nervous systems and plays a principal role in the etiology of IBS symptoms. The pharmacological studies on selective drugs based on targeting specific ligands can provide novel therapies for modulation of persistent visceral hyperalgesia. The current paper reviews the cellular and molecular mechanisms underlying therapeutic targeting for providing future drugs to protect or treat visceroperception and pain sensitization in IBS patients. There are a wide range of mediators and receptors participating in visceral pain perception amongst which substances targeting afferent receptors are attractive sources of novel drugs. Novel therapeutic targets for the management of VH include compounds which alter gut-brain pathways and local neuroimmune pathways.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • X351endoscopic Ultrasonography and Computed
    3rd UEGWOslo 1994 A9 viding the patients according to the criteria of Colin-Jones gave very small -8%, 95% Cl -22% to +7%). The response was unrelated to subgroups of groups and offered no further information. The effects of the drug on individ- dyspepsia: effects of CIS, NIZ and PLA, respectively, in R: 57%, 60%, and ual symptoms, likewise, did not reach significance. 74%, in D: 61%, 55%, and 55%, in U: 67%, 50%, and 60% and in I: 67%, Gut: first published as 10.1136/gut.35.4_Suppl.A9 on 1 January 1994. Downloaded from Conclusion: Our results do not support a role for gastric acid production 50%, and 64%. in generation of functional upper dyspepsia and do not warrant prescription Conclusion: effects of a 2-week course of CIS or NIZ in unselected patients of Omeprazole to patients suffering from non-ulcer dyspepsia. with NUD were not superior to effects of PLA. Symptom grouping was not predictive of response to therapy. 3 Effects of Fedotozine in Chronic Idiopathic Dyspepsia: A Double Blind, Placebo Controlled 351EndoscopicX Ultrasonography and Computed Multicentre Study Tomography in Diagnosis and Staging of Pancreatic Tumors: Comparison with Surgery J.P Galmiche 1, C. de Meynard 2, J.L. Abitbol 2, B. Scherrer2, B. Fraitag 2. 1 Service d'H6pato-Gastroent6rologie, CHU Nord, BP 1005, 44035 Nantes; J.M. Aubertin 1, 0. Marty1, J.L. Bouillot2, A. Hernigou3, F. Bloch 1, J.P 2 Institut de Recherche Jouveinal, BP 100, 94265 Fresnes Petite 1. 1 Dept of Gastroenterology, H6pital Broussais, 75014 Paris, France; 2 Dept ofSurgery, H6pital Broussais, 75014 Paris, France; 3 Dept of Safety and efficacy of fedotozine (F), a peripheral K agonist, were assessed Radiology, H6pital Broussais, 75014 Paris, France versus placebo (P), in a double blind multicentre study conducted in France by hospital and private gastroenterologists.
    [Show full text]
  • Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands
    Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands By Stephanie Nicole Johnson Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Masters in Science. Chairperson: Dr. Thomas E. Prisinzano Dr. Apurba Dutta Dr. Jeffrey P. Krise Date Defended: May 2, 2017 The Thesis Committee for Stephanie Nicole Johnson certifies that this is the approved version of the following thesis: Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands Chairperson: Dr. Thomas E. Prisinzano Date approved: May 4, 2017 ii Abstract The ability of ligands to differentially regulate the activity of signaling pathways coupled to a receptor potentially enables researchers to optimize therapeutically relevant efficacies, while minimizing activity at pathways that lead to adverse effects. Recent studies have demonstrated the functional selectivity of kappa opioid receptor (KOR) ligands acting at KOR expressed by rat peripheral pain sensing neurons. In addition, KOR signaling leading to antinociception and dysphoria occur via different pathways. Based on this information, it can be hypothesized that a functionally selective KOR agonist would allow researchers to optimize signaling pathways leading to antinociception while simultaneously minimizing activity towards pathways that result in dysphoria. In this study, our goal was to alter the structure of U50,488 such that efficacy was maintained for signaling pathways important for antinociception (inhibition of cAMP accumulation) and minimized for signaling pathways that reduce antinociception. Thus, several compounds based on the U50,488 scaffold were designed, synthesized, and evaluated at KORs. Selected analogues were further evaluated for inhibition of cAMP accumulation, activation of extracellular signal-regulated kinase (ERK), and inhibition of calcitonin gene- related peptide release (CGRP).
    [Show full text]
  • Selective Blockade of NK2 Or NK3 Receptors Produces Anxiolytic- and Antidepressant-Like Effects in Gerbils ⁎ N
    Pharmacology, Biochemistry and Behavior 83 (2006) 533–539 www.elsevier.com/locate/pharmbiochembeh Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils ⁎ N. Salomé, J. Stemmelin, C. Cohen , G. Griebel Sanofi-Aventis, Department of Psychopharmacology, 31 av Paul Vaillant-Couturier, 92220 Bagneux, France Received 17 October 2005; received in revised form 1 March 2006; accepted 9 March 2006 Available online 19 April 2006 Abstract There is a growing interest in the potential anxiolytic- and antidepressant-like effects of compounds that target neurokinin receptors. Since the structure and the pharmacology of the human neurokinin receptor resembles that of gerbils, rather than that of mice or rats, we decided to investigate the anxiolytic- and /or antidepressant-like effects of NK1 (SSR240600), NK2 (saredutant) and NK3 (osanetant) receptor antagonists in gerbils. It was found that saredutant (3–10 mg/kg, p.o.) and osanetant (3–10 mg/kg, p.o.) produced anxiolytic-like effects in the gerbil social interaction test. These effects were similar to those obtained with the V1b receptor antagonist SSR149415 (3–10 mg/kg, p.o.), diazepam (1 mg/kg, p.o.) and buspirone (10 mg/kg, p.o.). Fluoxetine and SSR240600 were devoid of effects in this test. In the tonic immobility test in gerbils, saredutant (5–10 mg/kg, i.p.) and osanetant (5–10 mg/kg, i.p.) produced similar effects to those observed with fluoxetine (7.5–15 mg/kg, i.p.), SSR149415 (10–30 mg/kg, p.o.) and buspirone (3 mg/kg, i.p.). Diazepam and SSR240600 were inactive in this paradigm.
    [Show full text]